Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052

被引：0
|
作者：
Spencer, Andrew [1 ]
Millward, Michael [2 ,3 ]
Mainwaring, Paul [4 ]
Harrison, Simon [5 ]
Catley, Laurence [6 ]
Townsend, Amanda [7 ]
Sukumaran, Shawgi [7 ]
Longenecker, Angie M. [8 ]
Palladino, Michael A. [8 ]
Lloyd, G. Kenneth [8 ]
Neuteboom, Saskia [8 ]
Padrik, Peeter [9 ]
Spear, Matthew A. [8 ]
Price, Timothy [7 ]
机构：
[1] Alfred Hosp, Melbourne, Vic, Australia
[2] Sir Charles Gairdner Hosp, Perth, WA 6000, Australia
[3] Univ Western Australia, Perth, WA 6009, Australia
[4] Mater Hosp, Brisbane, Qld, Australia
[5] Peter MacCallum Canc Inst, Dept Hematol, Melbourne, Vic 3000, Australia
[6] Mater Adult Hosp, Canc Serv, Brisbane, Qld, Australia
[7] Queen Elizabeth Hosp, Adelaide, SA, Australia
[8] Nereus Pharmaceut Inc, San Diego, CA USA
[9] Tartu Univ Hosp, Tartu, Estonia
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1053 / 1054
页数：2
相关论文
共 50 条
  • [21] NPI-0052 (a 2nd generation proteasome inhibitor) Phase 1 study in patients with lymphoma and solid tumors
    Kurzrock, R.
    Hamlin, P.
    Gordon, M.
    Hong, D.
    Fu, S.
    Younes, A.
    Hannah, A.
    Palladino, M. A.
    Spear, M. A.
    Aghajanian, C.
    EJC SUPPLEMENTS, 2008, 6 (12): : 73 - 74
  • [22] Results from phase 1 dose escalation study of the proteasome inhibitor NPI-0052 in patients with solid tumors and lymphomas
    Kurzrock, Razelle
    Hamlin, Paul
    Younes, Anas
    Hong, David
    Gordon, Michael
    Hannah, Alison
    Palladino, Michael A.
    Lloyd, G. Kenneth
    Longenecker, Angie M.
    Neuteboom, Saskia T. C.
    Cropp, Gillian F.
    Spears, Matthew A.
    Aghajanian, Carol
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3433S - 3433S
  • [23] Clinical trial combining proteasome (NPI-0052) and HDAC (vorinostat) inhibition in melanoma, pancreatic, and lung cancer
    Millward, Michael
    Spear, Matthew A.
    Townsend, Amanda
    Sweeney, Christopher
    Sukumaran, Shawgi
    Longenecker, Angie
    Palladino, Michael A.
    Lloyd, G. Kenneth
    Neuteboom, Saskia T.
    Price, Timothy
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [24] Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma
    Chauhan, Dharminder
    Singh, Ajita V.
    Ciccarelli, Bryan
    Richardson, Paul G.
    Palladino, Michael A.
    Anderson, Kenneth C.
    BLOOD, 2010, 115 (04) : 834 - 845
  • [25] Novel NFκB inhibitors NPI-1342 / NPI-1387 and proteasome inhibitor NPI-0052 overcome resistance of pancreatic carcinoma to rhTRAIL
    Khanbolooki, Sanaz
    Pino, Simona
    Andtbacka, Robert
    Chao, Ta-Hsiang
    Neuteboom, Saskia
    Palladino, Michael A.
    McConkey, David J.
    CANCER RESEARCH, 2006, 66 (08)
  • [26] Preclinical and clinical monitoring of cell-and circulating plasma specific proteasome biomarkers after treatment with the proteasome inhibitor, NPI-0052
    Palladino, M. A.
    Chao, T.
    Neuteboom, S. T. C.
    Spear, M.
    Ma, W.
    Albitar, M.
    EJC SUPPLEMENTS, 2008, 6 (12): : 74 - 74
  • [27] Pharmacodynamic profiling defines the significant biological activities of the novel proteasome inhibitor NPI-0052: Comparison with Velcade® (Bortezomib)
    Chao, Ta-Hsiang
    Chauhan, Dharminder
    Deyanat-Yazdi, Gordafaried
    Catley, Laurence
    Richardson, Paul
    Lloyd, G. Kenneth
    Neuteboom, Saskia T. C.
    Anderson, Kenneth C.
    Palladino, Michael A.
    CANCER RESEARCH, 2006, 66 (08)
  • [28] Phase I clinical trial of the 2nd generation proteasome inhibitor NPI-0052 in patients with advanced malignancies with a CLL RP2D
    Townsend, A.
    Padrik, P.
    Mainwaring, P.
    Price, T.
    Catley, L.
    Longenecker, A.
    Palladino, M. A.
    Lloyd, G. K.
    Spear, M. A.
    Millward, M.
    EJC SUPPLEMENTS, 2008, 6 (12): : 74 - 74
  • [29] Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model
    Singh, Ajita V.
    Palladino, Michael A.
    Lloyd, George Kenneth
    Potts, Barbara C.
    Chauhan, Dharminder
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 (04) : 550 - 559
  • [30] Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells
    Miller, Claudia P.
    Rudra, Sharmistha
    Keating, Michael J.
    Wierda, William G.
    Palladino, Michael
    Chandra, Joya
    BLOOD, 2009, 113 (18) : 4289 - 4299
12345